Page 3 - Best Liver cancer stage 2 doctors: TOP 90 doctors

A top specialist in Whipple and minimally invasive abdominal surgery, Dr. Greenberg heads the Colorectal Surgery Department at Sourasky Medical Center (Ichilov).

• Over 35 years of experience of experience as an abdominal surgeon
• Performs both open and minimally invasive surgical techniques
• Expert in complex pancreatic and liver procedures like Whipple surgery
• Leads a specialized surgical department at a major hospital

32 years of experience specializing in liver cancer surgery – Dr. Ben-haim is among Israel's top gastrointestinal cancer surgeons at Sourasky Medical Center.

• Expert in Whipple surgery for complex cases
• Focuses exclusively on liver, pancreatic, and gastrointestinal cancers
• Performs advanced interventions for oncological conditions

Univ. Prof. Dr. Wolfgang Köstler is a distinguished medical oncologist who helped pioneer targeted therapies – a core strategy for treating many liver cancers today.

• Over 22 years of experience of clinical, academic, and research experience in oncology
• Deputy Head of the Clinical Division of Oncology at Medical University of Vienna
• Expertise in individualized systemic therapy and immunotherapy
• Focuses on biomarker development and precision oncology strategies

Prof. Oldhafer specializes in liver cancer surgery at Asklepios Hospital Barmbek, where he leads a Centre for Liver Diseases.

• Expert in radioservice computer-navigated liver surgery
• Performs minimally invasive abdominal surgery
• Uses advanced techniques like ultrasonic knife
• Collaborates with oncology and radiology specialists

Associate Professor Tahsin Ozatli specializes in breast, lung, and gastrointestinal cancers, treating patients at Istinye Liv University Hospital.

• Internal Medicine Specialist with experience at multiple hospitals in Turkey
• Oncologist at Ankara Oncology Clinic and Erzurum Regional Training and Research Hospital
• Studied medicine at Selcuk University in Konya
• Promoted to Associate Professor in 2016

Associate Professor Dr. Yusuf Acikgoz brings specialized expertise in Medical Oncology, with training at Ohio State University and active involvement in international clinical trials.

• Participated in Phase III trials like CheckMate-649 and Fortitude-101
• Member of ASCO and Turkish Society of Medical Oncology
• Trained in immuno-oncology through CECOG courses in Vienna
• Certified in Good Clinical Practice and Human Subjects Protection

Dr. Liuying leads the Oncology Ward at Jinshazhou Hospital, Guangzhou University of Chinese Medicine. Clinical focus includes hepatocellular carcinoma, cholangiocarcinoma, and lung and colorectal cancers. Dr. Liuying has special expertise in melanoma and melanoma liver metastasis. Interventional skills include MWA, RFA, cryoablation, and radioactive seed implantation for non-vascular, minimally invasive tumor ablation.

Research: participated in two Guangdong Provincial science and technology projects. Contributed to the 2014 Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors. Published in the Chinese Journal of Lung Cancer. Compiled Selected Cases of Microwave Ablation for Lung Tumors and Selected Cases of Microwave Ablation for Liver Tumors.

Appointments: Standing Committee Member, Youth Committee of Intra-Tumor Brachytherapy Medicine, China Medical Education Association. Standing Committee Member, Minimally Invasive Interventional Medicine Professional Committee, Guangdong Primary Medical Association.

Specialized in laparoscopic and oncological cancer surgery with training at Istanbul University. Dr. Al focuses on minimally invasive techniques for liver cancer.

• Trained in advanced laparoscopic surgery at Cerrahpaşa Faculty of Medicine
• Performs laparoscopic bariatric and anti-reflux surgeries
• Graduated from Ondokuz Mayıs University Faculty of Medicine
• Specialized at KTÜ Faculty of Medicine Farabi Hospital

Dr. Ozden brings over 27 years of experience of expertise in oncology, honed through diverse clinical roles across Turkey.

• Specialized in medical oncology with a focus on liver cancer
• Trained at Istanbul University's renowned Cerrahpaşa Faculty of Medicine
• Extensive experience in both private and university hospital settings
• Committed to personalized treatment plans for each patient

Associate Professor Babek Tabandeh is an expert surgeon specializing in liver cancer and minimally invasive techniques. He performs complex liver surgeries at Medical Park Göztepe Hospital.

• Over of experience in general and cancer surgery
• Focuses on minimally invasive surgery for better recovery
• Published author with 40+ scientific papers
• Member of the prestigious American College of Surgeons
• Also holds membership in the Liver Transplantation Society

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Specializing in virotherapy – one of the newest immunology fields – Dr. Jaunalksne brings 49 years of experience of experience to liver cancer treatment.

• Head of Clinical Immunology Center at Pauls Stradins Clinical University Hospital
• Graduate of Riga Medical Institute with internship in Internal Medicine
• Focuses on cutting-edge immunological approaches to cancer

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Dr. Auala Hubert leads the Gastrointestinal Cancer Center at Hadassah Medical Center, bringing 36 years of experience of focused oncology expertise.

• Specializes in Medical Oncology & Radiotherapy
• Head of Gastrointestinal Cancer Center at Hadassah
• Board-certified in Oncology & Radiotherapy
• Member of Israel Society of Clinical Oncology
• Fluent in English and Hebrew for international patients

Assoc. Prof. Nail Paksoy is an ESMO-certified medical oncologist at Medipol Bahçelievler Hospital, specializing in liver cancer with extensive clinical trial experience.

• Completed fellowship at Istanbul University Oncology Institute
• Subinvestigator in 8 international oncology clinical trials
• Published multiple studies on cancer treatment efficacy
• Specializes in personalized treatment approaches

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.